Search research articles
Contact Us
Filters
Showing results (251-260 of 288) with videos related to
Page
of 29
Sort By:
Cancer Chemotherapy and Pharmacology
|
January 19, 2017
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer
Jeffrey R Infante, Amita Patnaik, Claire F Verschraegen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 23, 2015
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Kyriakos P Papadopoulos, Robin Kate Kelley, Anthony W Tolcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2024
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Aditya Bardia, Ian E Krop, Takahiro Kogawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Kyriakos P Papadopoulos, Melissa L Johnson, Albert C Lockhart, et al.
Investigational New Drugs
|
September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2012
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
Anthony W Tolcher, Wells A Messersmith, Stanislaw M Mikulski, et al.
Gynecologic Oncology
|
September 12, 2020
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martin, et al.
Journal for Immunotherapy of Cancer
|
October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
Albiruni Ra Razak, James M Cleary, Victor Moreno, et al.
British Journal of Cancer
|
February 3, 2017
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 28, 2016
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A Patnaik, L J Appleman, A W Tolcher, et al.
Page
of 29
Search research articles
Search
Showing results (251-260 of 288) with videos related to
Sort By:
Page
of 29
Cancer Chemotherapy and Pharmacology
|
January 19, 2017
Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer
Jeffrey R Infante, Amita Patnaik, Claire F Verschraegen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 23, 2015
A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Kyriakos P Papadopoulos, Robin Kate Kelley, Anthony W Tolcher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2024
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Aditya Bardia, Ian E Krop, Takahiro Kogawa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies
Kyriakos P Papadopoulos, Melissa L Johnson, Albert C Lockhart, et al.
Investigational New Drugs
|
September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2012
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors
Anthony W Tolcher, Wells A Messersmith, Stanislaw M Mikulski, et al.
Gynecologic Oncology
|
September 12, 2020
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Danny Rischin, Marta Gil-Martin, Antonio González-Martin, et al.
Journal for Immunotherapy of Cancer
|
October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
Albiruni Ra Razak, James M Cleary, Victor Moreno, et al.
British Journal of Cancer
|
February 3, 2017
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor
Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 28, 2016
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
A Patnaik, L J Appleman, A W Tolcher, et al.
Page
of 29